Evolent Health's (EVH) "Market Outperform" Rating Reaffirmed at JMP Securities

Evolent Health (NYSE:EVH - Get Free Report)'s stock had its "market outperform" rating reiterated by research analysts at JMP Securities in a note issued to investors on Friday,Benzinga reports. They presently have a $12.00 target price on the technology company's stock. JMP Securities' target price suggests a potential upside of 18.93% from the company's current price.

Several other equities analysts have also issued reports on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 price target on shares of Evolent Health in a research report on Wednesday, February 12th. UBS Group decreased their target price on shares of Evolent Health from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, January 16th. Truist Financial dropped their target price on shares of Evolent Health from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Wednesday, January 22nd. Oppenheimer reduced their price target on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a research report on Friday, January 24th. Finally, Citigroup lowered their price objective on Evolent Health from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $17.92.

Evolent Health Stock Up 0.7 %

EVH stock traded up $0.07 on Friday, reaching $10.09. 3,064,820 shares of the company traded hands, compared to its average volume of 2,121,901. The firm has a fifty day simple moving average of $10.82 and a 200-day simple moving average of $19.04. The company has a market cap of $1.18 billion, a P/E ratio of -11.09 and a beta of 1.45. Evolent Health has a one year low of $9.45 and a one year high of $35.00. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning boosted its holdings in shares of Evolent Health by 12.2% in the second quarter. Creative Planning now owns 18,091 shares of the technology company's stock worth $346,000 after buying an additional 1,973 shares during the last quarter. GAMMA Investing LLC raised its position in Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company's stock worth $45,000 after acquiring an additional 1,556 shares during the period. Friedenthal Financial purchased a new position in shares of Evolent Health during the 3rd quarter worth $723,000. Moody Aldrich Partners LLC bought a new stake in shares of Evolent Health during the 3rd quarter valued at $1,421,000. Finally, Values First Advisors Inc. grew its position in shares of Evolent Health by 21.0% during the 3rd quarter. Values First Advisors Inc. now owns 32,129 shares of the technology company's stock valued at $909,000 after acquiring an additional 5,583 shares during the period.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.